Market capitalization | $148.56m |
Enterprise Value | $-57.38m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.72 |
EV/Sales (TTM) EV/Sales | -0.84 |
P/S ratio (TTM) P/S ratio | 2.16 |
P/B ratio (TTM) P/B ratio | 0.73 |
Revenue growth (TTM) Revenue growth | -58.79% |
Revenue (TTM) Revenue | $68.68m |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
8 Analysts have issued a Repare Therapeutics Inc forecast:
8 Analysts have issued a Repare Therapeutics Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | 69 69 |
59%
59%
|
|
Gross Profit | 66 66 |
59%
59%
|
|
EBITDA | -92 -92 |
846%
846%
|
EBIT (Operating Income) EBIT | -95 -95 |
1,245%
1,245%
|
Net Profit | -69 -69 |
2,125%
2,125%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Repare Therapeutics Inc., a precision oncology company, discovers and develops novel therapeutics by using synthetic lethality approach in Canada. It provides SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The company's lead product candidate is RP-3500 a potent and selective oral small molecule inhibitor of ATR for the treatment of tumors with mutations in ataxia-telangiectasia mutated kinase. It also develops CCNE1-SL, a proprietary drug discovery program for tumors with amplification of CCNE1; and polymerase theta inhibitor. The company was founded in 2016 and is headquartered in St. Laurent, Canada.
Head office | Canada |
CEO | Lloyd Segal |
Employees | 179 |
Founded | 2016 |
Website | www.reparerx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.